BIOMARKER:

CDKN2A mutation

Entrez ID:

Related biomarkers:

‹

›

CDKN2A mutation CDKN2A mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials
CDKN2A mutation CDKN2A mutation	Breast Cancer Breast Cancer	ribociclib Resistant: B - Late Trials
CDKN2A mutation CDKN2A mutation	Gallbladder Cancer Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	palbociclib Sensitive: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Pancreatic Cancer Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Solid Tumor Solid Tumor	Immunotherapy Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Urothelial Cancer Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Biliary Tract Cancer Biliary Tract Cancer	toripalimab Resistant: C3 – Early Trials
CDKN2A mutation CDKN2A mutation	Penile Cancer Penile Cancer	nivolumab Sensitive: C4 – Case Studies
CDKN2A mutation CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	AZD1775 + VIC-1911 Sensitive: D – Preclinical
CDKN2A mutation CDKN2A mutation	Non Small Cell Lung Cancer NSCLC	AZD1775 + VIC-1911 Sensitive: D – Preclinical
CDKN2A mutation CDKN2A mutation	Melanoma Melanoma	palbociclib Sensitive: D – Preclinical